MISC

2002年

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

Metabolism: Clinical and Experimental
  • Hiroshi Hirose
  • ,
  • Toshihide Kawai
  • ,
  • Yukihiro Yamamoto
  • ,
  • Matsuo Taniyama
  • ,
  • Motowo Tomita
  • ,
  • Koichi Matsubara
  • ,
  • Yasunori Okazaki
  • ,
  • Tatsuya Ishii
  • ,
  • Yuko Oguma
  • ,
  • Izumi Takei
  • ,
  • Takao Saruta

51
3
開始ページ
314
終了ページ
317
記述言語
英語
掲載種別
DOI
10.1053/meta.2002.30506
出版者・発行元
W.B. Saunders

The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 ± 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 ± 14 to 101 ± 10 mm Hg), FPG (8.6 ± 1.4 to 7.0 ± 1.0 mmol/L), serum insulin (54 ± 11 to 30 ± 8 pmol/L, P &lt
.01 for all), and HbA1c (6.7 ± 0.8 to 6.1% ± 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 ± 3.2 to 27.0 ± 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 ± 24 to 138 ± 24 mg/dL) and SAT (155 ± 69 to 179 ± 81cm2, P &lt
.05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 ± 1.7 to 14.4 ± 2.1 μg/mL, P = .005). VAT tended to increase (165 ± 38 to 180 ± 46 cm2) and VAT/SAT ratio tended to decrease (1.2 ± 0.3 to 1.1 ± 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level. Copyright © 2002 by W.B. Saunders Company.

リンク情報
DOI
https://doi.org/10.1053/meta.2002.30506
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/11887166
ID情報
  • DOI : 10.1053/meta.2002.30506
  • ISSN : 0026-0495
  • PubMed ID : 11887166
  • SCOPUS ID : 0036125944

エクスポート
BibTeX RIS